EXTRAPOLATION IN TRIAL-BASED COST-EFFECTIVENESS MODELLING- IN SEARCH OF A STANDARD

Author(s)

Ekman M1, Charbonneau C2, Ramsberg J1, Jonsson L1, Sandin R3, Jonsson B4, Drummond M5, Weinstein MC61i3 Innovus, Stockholm, Sweden, 2Pfizer, Inc, New York, NY, USA, 3Pfizer Oncology, Sollentuna, Stockholm, Sweden, 4Stockholm School of Economics, Stockholm, Sweden, 5University of York, York, United Kingdom, 6Harvard School of Public Health, Boston, MA, USA

BACKGROUND: Extrapolation is often a key element in health economic modelling. Although any model should use empirical data if possible, the effects of treatments on long-term health outcomes are seldom observed within the follow-up time of a clinical study. Extrapolation over a lifetime horizon will generally be required in economic models where treatments have different cumulative survival at the end of the clinical trial. Typically a within-trial analysis of costs and health effects, in which outcomes are truncated at the conclusion of the trial, will be overly conservative. OBJECTIVES: The purpose of this study is to compare different methods of extrapolation in the context of examples concerning oncology, although the principles apply across all therapeutic areas.  METHODS: There is a set of standard assumptions regarding extrapolation of survival data from clinical studies, ranging from very cautious (‘stop-and drop”) to very optimistic (“continued benefit”). The impact of different assumptions regarding extrapolation is explored, and the implications are discussed. CONCLUSIONS:  The choice of extrapolation method has significant impact on comparative clinical effects, costs and cost effectiveness. Based on our findings and supporting examples, we propose the following: 1. Analysts should perform and report results under a range of specific standard extrapolation assumptions to increase comparability across studies.  2. The choice of a base-case approach in any particular study should be guided by knowledge about the biology of the indication under evaluation and the mechanism of action of the treatment.  A case could be made for a reference case method of extrapolation, but we believe that sensitivity analysis across a standard set of possibilities is sufficient.  Adherence to these modelling practices will contribute to increased transparency in modelling and hence potentially to a greater confidence among health care decision makers in the results from cost-effectiveness analyses building on modelling and extrapolation.

Conference/Value in Health Info

2010-11, ISPOR Europe 2010, Prague, Czech Republic

Value in Health, Vol. 13, No. 7 (November 2010)

Code

PCN162

Topic

Methodological & Statistical Research

Topic Subcategory

Modeling and simulation

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×